Mesirow Institutional Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mesirow Institutional Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$28.1K	Buy	427 +29	+7%	+$1.94K	﹤0.01%	129
2024 Q3	$28K	Sell	398 -40,390	-99%	-$3.38M	﹤0.01%	125
2024 Q2	$3.36M	Buy	40,788 +9,028	+28%	+$752K	0.29%	86
2024 Q1	$2.77M	Buy	31,760 +2,499	+9%	+$224K	0.25%	95
2023 Q4	$2.82M	Buy	29,261 +451	+2%	+$39.9K	0.26%	92
2023 Q3	$2.55M	Buy	28,810 +24,115	+514%	+$2.15M	0.26%	96
2023 Q2	$407K	Sell	4,695 -18,975	-80%	-$1.79M	0.04%	109
2023 Q1	$2.3M	Sell	23,670 -1,310	-5%	-$136K	0.25%	117
2022 Q4	$2.59M	Buy	24,980 +1,200	+5%	+$113K	0.34%	83
2022 Q3	$2.02M	Buy	+23,780	New	+$2.12M	0.29%	89

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Mesirow Institutional Investment Management's BMRN Position: Q4 2024 in Review

Mesirow Institutional Investment Management increased its BioMarin Pharmaceuticals (BMRN) stake by 7.3% in Q4 2024, buying an estimated $1.94K and bringing the position to 427 shares worth $28.1K. The position accounts for ﹤0.01% of the portfolio, ranked #129.

Mesirow Institutional Investment Management first reported a position in BMRN in Q3 2022 and has held it in 10 quarters since. The position peaked at $3.36M in Q2 2024. 544 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

Mesirow Institutional Investment Management held 427 shares of BioMarin Pharmaceuticals worth $28.1K as of Q4 2024.
Mesirow Institutional Investment Management bought 29 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $1.94K.
BioMarin Pharmaceuticals made up ﹤0.01% of Mesirow Institutional Investment Management's portfolio in Q4 2024, its #129 holding.
Mesirow Institutional Investment Management first reported a position in BioMarin Pharmaceuticals in Q3 2022 and has held it in 10 quarters since.
Mesirow Institutional Investment Management's BioMarin Pharmaceuticals position peaked at $3.36M in Q2 2024.
544 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on Mesirow Institutional Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.